LONDON, Sept. 18, 2026 — Nscale Limited (“Nscale”) today announced that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (“SEC”) relating to a proposed initial public offering of its ordinary shares. The number of shares to be offered and the price range for the proposed offering have not yet been determined. Nscale has applied to list its ordinary shares on the New York Stock Exchange under the ticker symbol “NSCL.”

Goldman Sachs & Co. LLC, J.P. Morgan and Morgan Stanley will act as lead bookrunners for the proposed offering. RBC Capital Markets, BofA Securities, Deutsche Bank Securities, Credit Agricole CIB, TD Securities, Mizuho, KeyBanc Capital Markets, Cantor, SMBC Nikko and Wolfe | Nomura Alliance will act as bookrunners for the proposed offering.  Citizens Capital Markets, Loop Capital Markets, Roth Capital Partners, ABN AMRO, Compass Point, DNB Carnegie, Rosenblatt, SEB and Tigress Financial Partners will act as co-managers for the proposed offering.

The proposed offering will be made available only by means of a prospectus. Copies of the preliminary prospectus, when available, may be obtained from: Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, New York 10282 or by email: [email protected]; J.P. Morgan Securities LLC, Attention: c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717 or by email: [email protected] and [email protected]; or Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick St., 2^nd Floor, New York, New York 10014.

A registration statement relating to these securities has been filed with the SEC but has not yet become effective. These securities may not be sold, nor may offers to buy be accepted, prior to the time the registration statement becomes effective. This press release does not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Nscale

Nscale Limited (Nscale) is a full-stack AI cloud platform. We bring together software, compute, and power in a vertically integrated offering – from a unified cloud platform for running AI training and inference, to the data centers and low-cost power that make it possible. Our mission is to build the engine of superintelligence and enhance access to the benefits of advanced AI for enterprises, governments, and the communities that depend on them.

SOURCE Nscale

DALLAS, Sept. 18, 2026 — Vestie is an investing platform designed for beginner investors, specifically women, who want to start investing but don’t know what to buy, when to start, or how to build a portfolio.

Vestie’s philosophy is simple: You don’t need to become a stock market expert to build wealth. Vestie is designed to help people start investing, automate the process, and stay invested for the long term. It’s your investing bestie — making investing feel more like getting help from a knowledgeable friend and less like walking into a Wall Street trading desk.

Founder and CEO Dana Bentz created Vestie after seeing how intimidating investing can feel to people who weren’t already immersed in finance. She built the product she wished existed when she first decided, “Okay, I know I should invest… Now what?” Most investment platforms were built around either active trading or traditional financial advisory experiences, and feature difficult-to-understand dashboards. Vestie is intentionally designed around simplicity, automation, and a beginner-friendly experience.

Users answer a short onboarding questionnaire regarding their investing goals, experience, and risk tolerance. They then receive a recommended diversified portfolio based on their unique answers, connect their bank account, fund their account, and can optionally set up recurring investments.

Vestie, Inc. is an investment adviser registered with the U.S. Securities and Exchange Commission*. Dana Bentz serves as the company’s CEO and as an investment adviser representative of Vestie, and says, “A lot of women know they should be investing. The problem isn’t convincing them that investing matters; it’s making that first step feel supported and simple enough to actually take.”

The company built a waitlist of roughly 500 people before public launch, demonstrating demand before the full product was available. Vestie is subscription-based rather than relying on users to constantly trade. Users can get started completely free, with access to advanced features for $14 per month or $139 per year. Vestie’s ambition is to become the financial platform women rely on when they decide they want to start investing and building wealth.

Vestie is available at https://vestie.com/, where users can create an account and begin investing.

*Registration with the SEC does not imply a certain level of skill or training.

Kelsey Bentz, [email protected]

SOURCE Vestie, Inc.

• ImpriMed combines ex vivo functional testing with multimodal AI to support personalized cancer treatment decisions and drug development
• The investment is part of ImpriMed’s $10 million Series A2 bridge round as the company advances U.S. commercialization and expands into Asia
• NAVER D2SF to strengthen its global healthcare founder community through its healthcare network and go-to-market expertise

SEOUL, South Korea, Sept. 18, 2026 — NAVER D2SF, NAVER’s inhouse corporate venture arm, has invested in ImpriMed, a Silicon Valley-based precision medicine company, joining ImpriMed’s $10 million Series A2 bridge round. ImpriMed develops AI-driven precision medicine solutions that combine ex vivo analysis of patient-derived live cancer cells with genomic, immunophenotypic, and clinical data to support personalized treatment decisions. NAVER D2SF’s investment reflects ImpriMed’s commercial and clinical experience in the U.S. healthcare market and its growing capabilities across precision medicine and drug development.

Precision oncology increasingly relies on integrating multiple types of patient data to account for differences in disease biology and treatment response. ImpriMed applies multimodal AI to patient-specific cancer cell characteristics, drug response profiles, and clinical information to enable more personalized treatment selection.

At the core of ImpriMed’s xCellSense^® platform is its ability to keep patient cancer cells viable ex vivo for extended periods, enabling evaluation of their biological characteristics and drug sensitivity. The platform combines these results with immunophenotypic, genomic, and clinical data to guide treatment decisions. ImpriMed is developing AI models trained on more than 3.5 million data points, combining real-world data with functional cell analysis to improve predictive accuracy.

ImpriMed is preparing to commercialize products for blood cancers and blood infection, targeting FDA clearance and CLIA certification by Q1 2027 for an initial U.S. launch. The company has also established business partnerships with major U.S. hospitals as it builds its human health presence in North America. In South Korea, ImpriMed has developed software for multiple myeloma prognosis and therapy-response predictions. The software has been designated an Innovative Medical Device by the Ministry of Food and Drug Safety (MFDS) and is progressing through the approval and commercialization process. ImpriMed also collaborates with leading tertiary hospitals, including Catholic University Seoul St. Mary’s Hospital, Seoul Asan Medical Center, and Gangneung Asan Hospital.

ImpriMed’s human healthcare expansion is supported by its commercial experience in veterinary precision oncology and its growing CRO business in drug development. In veterinary medicine, ImpriMed has performed more than 27,000 tests for canine and feline lymphoma to guide treatment decisions. A retrospective study showed a threefold increase in survival time and a fourfold improvement in treatment response, and the findings have been published in a peer-reviewed scientific journal. ImpriMed’s solutions are currently used by more than 600 veterinary hospitals across the United States, Canada, the United Kingdom, France, and South Korea.

ImpriMed was co-founded in Silicon Valley by CEO Sungwon Lim and CTO Jamin Koo, who studied together at KAIST and Stanford University. The company brings together expertise in biomedical research, AI modeling, clinical collaboration, and commercialization. Beyond North America, ImpriMed plans to expand into the European and Asian markets.

The $10 million bridge round follows ImpriMed’s $23 million Series A in 2023. The round was led by LB Investment, with participation from new investors NAVER D2SF, Samsung Securities, and Alois Ventures, as well as follow-on investments from existing investors BonAngels and Han River Partners.

NAVER D2SF continues to invest in healthcare startups targeting the North American market. Through NAVER D2SF’s founder network, portfolio companies such as Soundable Health, PranaQ, and NubiLab share local market knowledge and operating experience, fostering collaboration across R&D and go-to-market strategy.

About NAVER D2SF

NAVER D2SF is NAVER’s in-house corporate venture arm, supporting startups through investment and collaboration. Founded in 1999, NAVER has been Korea’s leading search engine for more than 20 years and operates across commerce, content, fintech, and cloud services. Guided by its technology vision of D2 (For Developers, By Developers), NAVER continues to develop new technologies and build global partnerships.

To learn more, visit https://d2sf.naver.com.

SOURCE NAVER D2SF

PLYMOUTH, Mich., Sept. 18, 2026 — Marel Power Solutions, Inc. announced today that it has been awarded $1.9 million through the Michigan Supplier Conversion Grant Program, administered by the Michigan Department of Labor and Economic Opportunity (LEO). Marel is one of eleven Michigan automotive suppliers selected to share $21 million in funding aimed at strengthening the state’s domestic automotive supply chain and preparing manufacturers for future vehicle technologies.

More information on the Michigan Supplier Conversion Grant Program and the 2026 award recipients is available through the Michigan Department of Labor and Economic Opportunity.

Marel Power develops power stacks, the building blocks inside every inverter and converter that moves energy between AC and DC, including electric vehicle traction inverters, battery disconnect units, onboard chargers, and charging infrastructure. It is a configurable platform rather than a component. The innovation is in how densely Marel Power packages power semiconductors and how aggressively it cools them. The platform is being deployed first in electric vehicles, and the same architecture extends to Defense and Data Center power systems.

“Power is the constraint on growth now,” said Amrit Vivekanand, CEO of Marel Power Solutions. “Customers need more power in less space, at lower weight, and lower cost. Marel can deliver the same power in roughly one-quarter of the space at 30% lower cost. This LEO funding gives us the equipment to build our power stacks at pilot scale here in Michigan. Because our platform is configurable and scalable, customers can select the configuration they need instead of paying for a new design from the ground up.”

The program is supported by the U.S. Department of Energy’s Domestic Automotive Manufacturing Conversion Grant program, which is intended to increase domestic manufacturing capacity for qualified vehicles and their components while helping established automotive suppliers adapt to changes in the industry.

The same demand for higher power density is accelerating across Data Center and AI infrastructure, where rapidly increasing compute requirements are driving more power through increasingly constrained physical footprints. Marel’s compact, high-density power electronics architecture is designed to help power conversion systems deliver significantly more power within the same (or smaller) space, supporting the next generation of AI and data center infrastructure.

“AI is changing the power-density requirements of the data center,” said Vivekanand. “The challenge is no longer simply delivering more power, it is delivering dramatically more power without requiring dramatically more space. That is exactly where Marel’s technology provides an advantage. By shrinking the power electronics footprint, we can help infrastructure providers use valuable space for compute instead of power conversion.”

For Marel Power, the award funds equipment for a pilot production line in Plymouth, beginning with electric vehicle applications.

About Marel Power Solutions

Marel Power Solutions is tackling the power challenge that will define the next decade of growth. Its configurable power stack platform shrinks the inverter at the heart of every high-power system, giving data centers more compute per rack, automakers lighter and lower-cost EV powertrains, and defense platforms smaller, lighter vehicles without sacrificing performance. Headquartered in Plymouth, Michigan, Marel lets customers order a configuration instead of funding a new design from scratch. Learn more at marel-power.com.

SOURCE Marel Power Solutions

• CEO Kwak Noh-Jung and key executives, alongside global VCs and startup leaders, attend the inaugural ‘SK hynix Ventures Day’ in Silicon Valley
• Company to expand investments across the entire AI ecosystem
• Discussing strategies to strengthen partnerships with global venture firms and investors in future technology fields such as AI data centers and optical-based systems

SEOUL, South Korea, Sept. 18, 2026 — SK hynix Inc. (or “the company”, www.skhynix.com) announced today the launch of its corporate venture capital (CVC) brand, “SK hynix Ventures,” aimed at expanding strategic partnerships within the global AI ecosystem and securing future innovative technologies.

To mark the occasion, SK hynix held the inaugural “SK hynix Ventures Day” in Silicon Valley, where executives shared investment strategies with global venture capitalists and startup representatives while discussing future technological cooperation to respond to shifts in the AI industry.

The event was attended by CEO Kwak Noh-Jung and key executive leadership, alongside representatives from global VC firms and executives from leading startups.

• Expanding Beyond Tech Sensing to Become a Strategic Partner in the AI Ecosystem

Since 2015, SK hynix has operated a CVC organization, pursuing both direct investments and indirect investments via fund commitments in promising early-stage startups within the semiconductor and emerging tech sectors. By investing in enterprises across key regions including the U.S., China, Israel, and Japan, the company has achieved returns exceeding twice its cumulative investment to date. Furthermore, it has accumulated a track record of discovering new supply chains and customers by pursuing technological collaborations—such as joint equipment development and Proof of Concept (PoC)—with portfolio companies.

While past CVC activities focused primarily on “Tech Sensing” to explore future technology trends and “Path Finding” to discover new business opportunities, the company now plans to expand its CVC scope. Driven by recent advancements in AI technology and industry expansion, the role will evolve from simply discovering promising companies to leading collaborative innovation across the entire ecosystem.

• Discussing Cooperation in AI Computing, Data Centers, and Optical Interconnect

Through SK hynix Ventures, the company plans to broaden its investment scope from traditional semiconductors and emerging tech to the broader AI ecosystem. SK hynix aims to discover technologies and companies with high growth potential in core AI industry sectors—including AI computing, data centers, system software, and optical interconnect—and continually expand its CVC investments.

Meanwhile, the event was attended by promising startups in the U.S. AI computing and data center technology sectors. These companies shared perspectives on future technological innovations, discussing the growing importance of computing, memory, and system software innovations driven by advanced AI models, alongside the performance and power efficiency of optical-based systems for AI data centers.

“Competitiveness in the AI era stems not just from rapidly securing innovative technologies, but from ecosystem capabilities where customers, partners, and startups create new value together,” said Kwak Noh-Jung, CEO of SK hynix. “Through SK hynix Ventures, we will support the growth of promising companies and grow into a global partner that jointly designs the future of AI infrastructure based on strategic investments and technological cooperation.”

About SK hynix Inc.
SK hynix Inc., headquartered in Korea, is the world’s top-tier semiconductor supplier offering Dynamic Random Access Memory chips (“DRAM”) and flash memory chips (“NAND flash”) for a wide range of distinguished customers globally. The Company’s common shares are traded on the Korea Exchange, its American Depositary Shares are traded on NASDAQ, and its Global Depository Shares are listed on the Luxembourg Stock Exchange. Further information about SK hynix is available at www.skhynix.com, news.skhynix.com.

SOURCE SK hynix Inc.

HCTI to serve as U.S. technology and capital-markets partner, bringing AI, cloud and data expertise as ARCB and Kanzun launch cross-border healthcare investment platform

PLEASANTON, Calif., Sept. 17, 2026 — Healthcare Triangle, Inc. (Nasdaq: HCTI) (“HCTI” or the “Company”), a U.S.-based healthcare technology company, today announced that it has signed on as the U.S. technology and capital-markets partner for a new fund built to move Malaysian healthcare companies to the world stage. The Kanzun-ARCB Growth Fund launched through a Memorandum of Understanding signed in Kuala Lumpur, Malaysia, pairing Dubai-based ARCB Investment LLC’s (“ARCB”) capital network with Kanzun Ventures Management Sdn. Bhd.’s (“Kanzun”) deal experience on the ground in Malaysia. HCTI’s role will be to get qualifying companies ready, technologically and financially, for a successful run at the U.S. capital markets.

ARCB brings roughly AED 300 million in assets under management and a network of family offices, institutional investors and strategic partners across the Middle East and Asia. The firm opened its Asia-Pacific office in Kuala Lumpur in April 2026, and the Kanzun-ARCB Growth Fund marks its first major platform launch in the region. Together with Kanzun and HCTI, the three parties are building a structured corridor connecting Malaysian healthcare companies to Middle Eastern capital and, from there, to U.S. capital markets.

How the Partnership Will Work

Kanzun will lead the deal sourcing, due diligence, valuation and portfolio development in Malaysia, identifying healthcare companies with real growth potential. ARCB anchors the fund’s capital formation, drawing on its investor network across the Middle East and Asia. HCTI steps in once a target companies are ready for thier next stage of growth. The Company applies its Nasdaq-listed experience and its expertise in artificial intelligence, cloud, data and digital infrastructure to help build the technology foundation and market readiness a U.S. expansion requires.

Management’s Comments

Dr Suresh Venkatachari, Founder and Head of M&A of Healthcare Triangle, Inc., said: “We are pleased to collaborate with ARCB and Kanzun Ventures in evaluating opportunities within the Malaysian AI and healthcare sector. We look forward to supporting qualifying companies in their AI technology transformation and evaluating appropriate strategic pathways to expand in U.S. markets.”

Dr Chaskar U., Chief Executive Officer of ARCB Group, said: “Since establishing our ASEAN presence in Kuala Lumpur this April, we have been deliberate about where and how ARCB deploys capital in this region. Malaysia’s healthcare sector is full of founders who have built genuinely strong businesses but have not yet had access to the institutional capital, governance and international positioning needed to compete globally. That is precisely the gap ARCB exists to close. With Kanzun’s execution capability on the ground and Healthcare Triangle’s technology and U.S. market experience, we are building more than a fund — we are building a corridor that connects Malaysian healthcare champions to Middle Eastern capital and, from there, to the U.S. capital markets. This is what our ASEAN strategy was always designed to deliver.”

Mr Loganathan S., Chief Executive Officer of Kanzun Ventures Management Sdn. Bhd., said: “Malaysia has healthcare entrepreneurs who have spent many years building strong businesses, but many of these companies remain relatively small from an international capital-market perspective. Working with ARCB gives us access to an international capital network, while our collaboration with Healthcare Triangle provides an important connection to healthcare technology and the U.S. market.”

About Healthcare Triangle, Inc.

Healthcare Triangle, Inc. (Nasdaq: HCTI), based in Pleasanton, California, reinforces healthcare progress through breakthrough technology and extensive industry knowledge and expertise. The Company supports healthcare organizations — including hospitals and health systems, payers, and pharma/life sciences organizations — in their effort to improve health outcomes through better utilization of the data and information technologies they rely on. Healthcare Triangle’s Cloud and Data Platform (CaDP), marketed as CloudEz™ and DataEz™, has achieved HITRUST Risk-based, 2-year (r2) Certified status, demonstrating to clients the highest standards for data protection and information security. Healthcare Triangle enables the adoption of new technologies, data enlightenment, business agility, and response to immediate business needs and competitive threats. The highly regulated healthcare and life sciences industries rely on Healthcare Triangle for expertise in digital transformation encompassing cloud, security and compliance, data lifecycle management, healthcare interoperability, and clinical and business performance optimization.

About ARCB Investment LLC

ARCB Investment LLC is a UAE fund house established in 2022 and a Mainland investment management licensed company (License No. 1041252), under the leadership of Chairman His Excellency Dr Mohammed Saeed Al Kindi, a former UAE Minister and diplomat, and Chief Executive Officer Dr Chaskar U. ARCB manages assets under management of approximately AED 300 million across ten sectors, including energy, water, healthcare, education, agriculture, industry, tourism, sports, technology and commercial real estate. ARCB is a participant of the United Nations Global Compact.

About Kanzun Ventures Management Sdn. Bhd.

Kanzun Ventures Management Sdn. Bhd. is a Malaysia-based venture capital management corporation registered with the Securities Commission Malaysia. Kanzun focuses on identifying, structuring and developing investment opportunities with the potential for significant growth and strategic value, including opportunities across healthcare and healthcare-related industries.

Forward-Looking Statements and Safe Harbor Notice

This press release contains forward-looking statements concerning the proposed collaboration among Healthcare Triangle, Inc., ARCB Investment LLC and Kanzun Ventures Management Sdn. Bhd., including statements regarding potential investments, acquisitions, capital raising, technology integration, strategic transactions and potential U.S. capital-market opportunities for Malaysian healthcare companies. References to targeted healthcare companies or segments in this announcement should not be interpreted as confirmation that any acquisition, investment, consolidation or U.S. listing has been completed. Any proposed transaction remains subject to due diligence, audit, valuation, negotiations, corporate and regulatory approvals, financing and the execution of definitive agreements. Nothing contained in this announcement constitutes an offer to sell or a solicitation of an offer to purchase securities or interests in any fund, company or investment vehicle. Any reference to Nasdaq or the U.S. capital markets represents a strategic objective or potential pathway only and does not constitute a representation or guarantee that any company will be listed on Nasdaq or complete any U.S. capital-market transaction.

All statements other than statements of historical facts included in this press release are “forward-looking statements” (as defined in the Private Securities Litigation Reform Act of 1995). Such forward-looking statements include our expectations and those statements that use forward-looking words such as “projected,” “expect,” “possibility” and “anticipate.” The achievement or success of the matters covered by such forward-looking statements involve significant risks, uncertainties, and assumptions, including market and other conditions. Actual results could differ materially from current projections or implied results. Investors should read the risk factors outlined in the Company’s annual report on Form 10-K for the year ended December 31, 2025, on file with the Securities and Exchange Commission (the “SEC”) and in previous filings, subsequent filings and future periodic reports filed with the SEC. All the Company’s forward-looking statements are expressly qualified by all such risk factors and other cautionary statements.

Investor Contact

Healthcare Triangle, Inc.
1-800-617-9550
[email protected]

SOURCE Healthcare Triangle, Inc.

Silicon Valley lender is building a private-bank-style mortgage platform for founders, self-employed entrepreneurs, business owners and high-net-worth borrowers who don’t fit traditional agency underwriting

DANVILLE, Calif., Sept. 17, 2026 — As Non-QM mortgage lending continues to expand, RateSecure sees the market separating into two distinct segments: traditional alternative-credit lending and a private-bank-style approach designed for financially strong borrowers with complex income and wealth profiles.

“There are really two Non-QM markets emerging — traditional alternative-credit lending and private-bank-style lending for wealthy borrowers,” said Gurp Bhandal, Founder and CPO of RateSecure. “We built RateSecure around the second.”

For RateSecure, this is often a documentation gap, not a credit gap.

“Traditional mortgage underwriting works well for borrowers with predictable W-2 income, but entrepreneurship creates a different financial profile,” said Sam Bhandal, President and CEO of RateSecure. “A successful business owner shouldn’t become a difficult mortgage borrower simply because their income doesn’t fit neatly into a conventional calculation.”

For many self-employed borrowers, legitimate business deductions, reinvestment and multiple income sources can complicate qualification without necessarily indicating weaker financial strength.

Private-Bank Thinking at Silicon Valley Speed

Understanding a complex borrower is only part of the equation. In Silicon Valley’s ultra-competitive housing market, execution matters just as much as loan structure.

RateSecure is built to close complex loans in less than 10 days, giving founders, entrepreneurs and business owners the ability to compete on speed alongside borrowers with traditional W-2 income.

Complex wealth shouldn’t put a buyer at a competitive disadvantage.

“When a family finds the right home, the complexity of how they’ve built their wealth shouldn’t be the reason they lose it,” Gurp Bhandal said. “Our job is to understand the borrower, structure the financing correctly and execute at the speed the market demands.”

A Different Evolution of Non-QM

RateSecure believes the growth of self-employment, entrepreneurship and complex personal wealth is changing the role Non-QM plays in the mortgage industry.

Historically, Non-QM has often been viewed as an alternative for borrowers unable to qualify for conventional financing. RateSecure believes that definition increasingly misses an important part of the market.

“Non-QM isn’t simply about borrowers who can’t qualify conventionally,” Gurp Bhandal said. “There’s a growing segment of financially strong borrowers who simply need a more sophisticated way to document income and wealth.”

For RateSecure, those borrowers aren’t exceptions to its lending model. They are the reason the model exists.

“We’re building a mortgage company around founders, entrepreneurs, business owners and high-net-worth borrowers,” Sam Bhandal said. “The goal is to bring the level of understanding and individualized structuring associated with private banking into a modern mortgage platform.”

About RateSecure Financial

RateSecure Financial, Inc. is a California mortgage lender focused on founders, self-employed entrepreneurs, business owners, real estate investors and high-net-worth borrowers with complex income and wealth.

Complex Wealth. Strategic Lending. Exceptional Execution.

RateSecure Financial, Inc.
NMLS #2815879
CA DFPI California Financing Law License #60DBO-217750
675 Hartz Avenue, Suite 103
Danville, CA 94526
(866) 351-RATE
[email protected]

SOURCE RateSecure

LAFAYETTE, Ind. , Sept. 17, 2026 — Valley Oaks Health announced today that it has been awarded $828,375 through the Growing Rural Opportunities for Well-being (GROW) Region 3 Grant initiative to strengthen access to integrated healthcare services across rural communities in northwest central Indiana.

The funding is part of the Indiana Rural Health Transformation Program (Indiana RHTP), a statewide initiative designed to improve healthcare access, strengthen healthcare infrastructure, promote innovation, and support strategic partnerships that improve the health and well-being of Hoosiers.

Valley Oaks Health serves individuals and families across ten Indiana counties through a comprehensive system of behavioral health, primary care, addiction treatment, crisis intervention, care coordination, and community-based support services. The GROW award will help advance efforts to improve access to care, strengthen regional partnerships, and enhance services in rural communities where healthcare workforce shortages and transportation barriers often limit access to timely treatment.

At the community level, this funding will primarily support expansion of Primary Care access points in Attica, IN and Monticello, IN in the first half of CY2027 with further expansion planned next year.

“This investment reflects a shared commitment to improving the health and well-being of rural Hoosiers,” said Dan Arens, Chief Executive Officer of Valley Oaks Health. “Through collaboration with community partners and local stakeholders, we will continue expanding access to integrated healthcare services that address both physical and behavioral health needs close to home; encouraging local healthcare relationships.”

Approximately one in five Hoosiers lives in a rural community, and the Indiana Rural Health Transformation Program supports community-driven solutions that address local healthcare priorities. The five-year initiative emphasizes innovation, workforce development, infrastructure improvements, and regional collaboration to improve health outcomes across Indiana.

Valley Oaks Health remains committed to its mission of improving the health and happiness of our community, one person at a time, by delivering accessible, high-quality care regardless of an individual’s ability to pay.

About Valley Oaks Health

Valley Oaks Health is a nonprofit healthcare organization serving communities across northwest central Indiana. The organization provides integrated behavioral health, primary care, addiction treatment, crisis services, and community support programs designed to improve the health and well-being of individuals and families throughout the region.

www.valleyoaks.org

This Rural Health Transformation Program is supported by the Centers for Medicare & Medicaid Services (CMS) of the U.S. Department of Health and Human Services (HHS) as part of a financial assistance award totaling $206,927,896.80 with 100 percent funded by CMS/HHS. The contents are those of the author(s) and do not necessarily represent the official views of, nor an endorsement, by CMS/HHS, or the U.S. Government.

SOURCE Valley Oaks Health

LONDON, Sept. 17, 2026 /PRNewswire/ — Magentic, which provides AI digital workers for operations at large industrial companies, today announced an $18 million Series A. The round was raised a year after launch and led by Felicis, alongside existing investors Sequoia Capital and The Westly Group. Founded by McKinsey and OpenAI alumni, Magentic is leading the deployment of AI agents for the world’s largest manufacturers.

“The physical world is dealing with the biggest capex cycle in history, driven by AI demand, during a time of trade disruption and geopolitical challenges,” said Robin Van Aeken, CEO and co-founder of Magentic. “The companies that build the best intelligence into every decision they make will be the ones that compound their competitive advantage.”

The funding arrives as industrial and procurement teams face converging pressures from manufacturing demand, tariffs, and limited budget. Goldman Sachs projects roughly $8 trillion in AI capital spending between 2026 and 2031, much of it flowing into physical infrastructure that has to be sourced and built. Procurement workloads have grown roughly 10% year over year against just 1% budget growth.

AI digital workers for operations

Magentic’s AI digital workers are multi-agent systems that operate like virtual employees, working continuously inside the world’s largest manufacturers. This AI workforce works the way people do: on Microsoft Teams, on email, and inside a company’s own systems. They can take over work and own it end to end: deciding whether to buy or build, choosing the right supplier, negotiating contracts, running orders, and clearing invoices. Built for a scale only the world’s largest manufacturers face in billions of rows of data, tens of billions in spend, and decades-old fragmented systems still held together by Excel and aging ERPs, a single digital worker grows into a workforce spanning operations, with people always in command.

Magentic supports both indirect and direct spend. This includes the raw materials that go into products, where the most complex and valuable challenges lie. One customer now runs more than a million orders a year through Magentic AI agents; at another, they’ve already found $4 million in savings. Across a base of the Global 500, including three of the world’s ten largest beverage companies, Magentic typically delivers 2–5% savings, a 60% lift in data quality, and reduces tens of thousands of hours of manual work. This frees people to focus on partnering with suppliers, new product innovation, and strategy. Magentic sees human procurement teams growing bigger as their value per person goes up in the future.

“Supply chains are the least glamorous part of the economy, yet the most consequential, deciding what gets built and what does not. That’s also what makes them so hard to automate,” said Feyza Haskaraman, Partner at Felicis. “Getting an agent to understand a manufacturer’s complex systems well enough to take action inside them is no small feat, which is why we haven’t seen anyone else build autonomous AI workers for the physical economy.”

Scaling a secure AI workforce

With enterprise wary of AI agents acting inside critical systems, Magentic is built for demanding security bars. Controls include zero-data-retention agreements with major AI providers, deployment in any cloud environment, and secure, isolated deployments available in any data region.

The new funding will accelerate Magentic’s roadmap for AI agents, extend coverage across procurement and supply chain workflows, and deepen the long-horizon AI research that lets agents tackle the most complex optimization problems in procurement and supply chains.

“Bringing frontier AI to the physical world requires pushing beyond AI systems with limited context windows. We’re building AI that can diagnose problems, plan the fixes, take action, and see the work through across terabytes of multimodal data at once,” said Odhran O’Donoghue, CTO and co-founder of Magentic.

About Magentic

Magentic provides AI digital workers, advanced multi-agent systems, that work alongside procurement and supply chain teams at global companies. Rather than adding another software dashboard, AI digital workers take action inside a company’s own systems. Founded by Robin Van Aeken (CEO) and Odhran O’Donoghue (CTO), Magentic launched in July 2025, is based in London and New York, and is backed by Sequoia Capital, Felicis, and The Westly Group.

Media contact 
media@magentic.com

SOURCE Magentic